Axsome Therapeutics, Inc. - AXSM Net Assets per Single Share

Axsome Therapeutics (AXSM) - corporate logo

This price chart for Axsome Therapeutics (AXSM) illustrates the asset's dynamics, with a value of 1.60. The business relies on demand that is independent of economic downturns or seasonal factors. Axsome Therapeutics (AXSM) is implementing cutting-edge developments to combat Alzheimer's disease and depression. The company is currently shifting its focus toward the monetization of its products, diversifying risks across various types of neuropathic drugs.

Axsome (AXSM) Equity per Share: for the period 07/04/2022 - 10/26/2026

axsome.com - analytical breakdowns and key metrics (AXSM)

- price and consensus price forecast:
Price Chart Axsome Therapeutics Inc|AXSM - Analyst Median Target
- market capitalization data:
Market Value Axsome Therapeutics, Inc.|AXSM - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Axsome Therapeutics|AXSM - Accounting Capitalization|Market Capitalization to Book Value Ratio axsome.com|AXSM - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Axsome Therapeutics|AXSM - Long-Term Debt to Capital|Short-Term Debt to Equity Axsome Therapeutics, Inc.|AXSM - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Axsome Therapeutics, Inc.
Fundamental company valuation:Axsome Therapeutics Inc, AXSM
Manufactured products of Axsome Therapeutics, Inc.

Book value per share reflects the portion of net assets attributable to a single security after deducting all liabilities. For Axsome Therapeutics (AXSM), this metric confirms resource capitalization amid the sales expansion of migraine and depression medications. The trend in book value per share demonstrates real capital density stripped of market noise. The stability of these lines excludes unjustified speculative premiums. Investors should utilize this metric as a conservative foundation for assessing the issuer's intrinsic value.

Competitors of Axsome Therapeutics (AXSM)

Net Assets per Single Share BIIB (Biogen Corp)|NBIX: Net Assets per Share|RGC (Regencell Bioscience) - Net Assets per Single Share|ACAD (acadia-pharm.com) - Accounting Value per Share|Net Assets per Single Share Xenon (XENE)|Equity per Share Viking Therapeutics Inc|Supernus Pharma - Book Value per Share|Net Asset Value per Share Catalyst Corp CPRX|Accounting Value per Share DNLI (Denali Therapeutics)|harmonybiosciences.com - Book Value per Share|Net Assets per Single Share Biohaven (BHVN)|AMLX: Accounting Value of a Share|Net Assets per Single Share TRVI|Praxis Corp (PRAX) - Net Asset Value per Share|AVXL (Anavex Life Sciences) - Book Value per Share|Book Value per Share ceribell.com (CBLL)|Accounting Value per Share Prothena Biosciences PRTA|Equity per Share ALEC (alector.com)|Net Assets per Single Share ANNX|Omeros Corp - Net Assets per Share|NGNE (Neurogene Inc.) - Net Assets per Single Share|ACIU: Net Asset Value per Share|VYGR (Voyager Therapeutics, Inc.) - Net Assets per Single Share|Neumora (NMRA) - Accounting Value per Share|Book Value per Share SCLX (Scilex Holding Co.)|Net Asset Value per Share Tevogen Bio Inc. (TVGN)|Alpha Cognition (ACOG) - Accounting Value per Share|Accounting Value of a Share Cognition Therapeutics Inc. CGTX|Accounting Value per Share Inhibikase Therapeutics, Inc. (IKT)|Book Price of a Share Cassava Sciences Inc SAVA|Book Value per Share Assertio Therapeutics (ASRT)|COYA - Accounting Value of a Share|Book Value per Share VTGN|OVID (Ovid Therapeutics) - Net Asset Value per Share|ABOS - Net Assets per Single Share|Accounting Value of a Share CervoMed, Inc.|Book Value per Share ATHE|Book Value per Share CLNN (clene.com)|PepGen (PEPG) - Net Assets per Single Share|Share Book Value Jupiter Neurosciences, Inc. JUNS|RLMD (Relmada Therapeutics, Inc.) - Book Value per Share|Annovis Bio Inc (ANVS) - Net Asset Value per Share|GRCE: Accounting Value per Share|Book Value per Share Firefly Neuro|ANEW Medical (KLTO) - Accounting Value per Share|Book Price of a Share NeuroSense Therapeutics, Ltd.|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - Book Value per Share|Net Assets per Share metaviatx.com (MTVA)|NeurAxis, Inc - Book Value per Share|Helius Medical Technologies, Inc. - Accounting Value per Share|Net Assets per Single Share PASG (Passage Bio Corp)|NEUP - Net Assets per Share|NERV: Book Value per Share|Book Value per Share Athira Pharma Inc|Accounting Value per Share Addex Therapeutics, Ltd. (ADXN)|Equity per Share ALZN|CYCN (Cyclerion Therapeutics) - Net Assets per Single Share|Net Assets per Share PTIX (protagenic.com)|Pasithea Therapeutics Corp. - Net Assets per Single Share|Cortigent Inc - Accounting Value per Share|Avenue Therapeutics, Inc (ATXI) - Net Assets per Single Share|BCLI - Equity per Share|Book Value per Share CARA|Net Asset Value per Share chromocell.com|ELYM (Eliem Therapeutics, Inc.) - Accounting Value per Share|Book Value per Share ITCI|Longboard Pharma (LBPH) - Net Assets per Single Share|Accounting Value of a Share MRNS (Marinus Pharma)|NKGN: Net Assets per Single Share|Net Asset Value per Share neurobopharma.com NRBO|Sage Therapeutics - Book Value per Share|Synaptogenix Inc. (SNPX) - Book Value per Share|Accounting Value per Share Trevena, Inc|VIGL (Vigil Neuroscience, Inc.) - Equity per Share|WENA: Net Assets per Single Share|Net Assets per Share CERE